|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I've been in Switzerland this week across Basel and Visp to visit drugmakers, including Novartis and Roche. Read below to find out how the Swiss biopharma scene is faring and Lonza's plan to dominate the ADC space. |
|
|
|
Anna Brown |
Biopharma Breaking News Reporter, Endpoints News
|
|
|
|
 |
|
A worker at Lonza's facility in Stein, Switzerland (Credit: Lonza) |
|
|
|
by Anna Brown
|
BASEL, Switzerland— Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next... | |
|
|
|
|
|
|
by Ayisha Sharma
|
BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings releasethat up to 1,860 manufacturing staff could... | |
|
|
|
|
|
|
by Max Bayer
|
Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest... | |
|
|
|
 |
|
Swiss Biotech Day 2026 (Credit: Swiss Biotech Association) |
|
|
|
by Anna Brown
|
BASEL, Switzerland— Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact... | |
|
|
|
|
|
|
by ENDPOINTS
|
Plus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolsterits
biologics... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's... | |
|
|
|
|
|
